#1 Clinical Trials Search in Europe

Varnimcabtagene Autoleucel

Varnimcabtagene Autoleucel, also known as ARI-0001, is an innovative CAR T-cell therapy being studied in clinical trials for the treatment of certain blood cancers. This therapy involves modifying a patient’s own T-cells to target and fight cancer cells expressing the CD19 protein. The ongoing trials are evaluating its effectiveness and safety in patients with relapsed or refractory non-Hodgkin lymphoma, acute lymphoblastic leukemia, and other CD19-positive blood cancers.

Table of Contents

What is Varnimcabtagene Autoleucel?

Varnimcabtagene autoleucel, also known as ARI-0001, is an innovative type of cancer treatment called CAR T-cell therapy. It belongs to a class of treatments known as advanced therapy medicinal products (ATMPs), specifically a gene therapy medicinal product.[1] This therapy uses a patient’s own immune cells, which are genetically modified to target and fight cancer cells more effectively.

How Does It Work?

Varnimcabtagene autoleucel works by modifying a patient’s T-cells, which are a type of white blood cell crucial for immune function. The process involves:

  1. Collecting T-cells from the patient’s blood through a process called leukapheresis
  2. Modifying these T-cells in a laboratory using a lentivirus to introduce a gene that produces a chimeric antigen receptor (CAR)
  3. The CAR is designed to target CD19, a protein found on the surface of certain cancer cells
  4. These modified T-cells are then multiplied in the laboratory
  5. Finally, the CAR T-cells are infused back into the patient’s bloodstream

Once in the body, these modified T-cells can recognize and attack cancer cells that express CD19 on their surface.[2]

Medical Conditions Treated

Varnimcabtagene autoleucel is being studied for the treatment of several types of blood cancers, including:

  • Acute Lymphoblastic Leukemia (ALL): A type of cancer that affects the blood and bone marrow, causing the rapid growth of abnormal white blood cells.[3]
  • Non-Hodgkin Lymphoma (NHL): A group of blood cancers that develop in the lymphatic system.[1]

Specifically, the therapy is being investigated for patients with relapsed or refractory (resistant to treatment) forms of these cancers, meaning their disease has either returned after initial treatment or did not respond well to standard therapies.

Clinical Trials

Several clinical trials are currently underway to evaluate the safety and efficacy of varnimcabtagene autoleucel:

  • A phase II study comparing ARI-0001 to commercial CAR T-cells (axicabtagene ciloleucel) in adults with relapsed/refractory non-Hodgkin lymphoma[1]
  • A phase II study in adults with relapsed/refractory CD19+ acute lymphoid leukemia[2]
  • A phase II study in children and adolescents (ages 0-18) with relapsed/refractory CD19+ acute lymphoblastic leukemia[3]

These trials aim to assess various aspects of the treatment, including its effectiveness in achieving remission, duration of response, overall survival, and safety profile.

Administration and Dosage

Varnimcabtagene autoleucel is administered as an intravenous infusion. The exact dosage can vary, but clinical trials have used doses ranging from 1 to 3 million CAR T-cells per kilogram of body weight, with a maximum total dose of 2-3 million cells.[2][3] The treatment is typically given as a single infusion, though some protocols may involve split dosing over multiple days.

Potential Side Effects

As with other CAR T-cell therapies, varnimcabtagene autoleucel can cause significant side effects. The most notable include:

  • Cytokine Release Syndrome (CRS): A systemic inflammatory response that can cause fever, low blood pressure, and organ dysfunction
  • Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS): Neurological side effects that can range from mild confusion to more severe symptoms like seizures or coma
  • B-cell aplasia: A reduction in normal B-cells, which can increase the risk of infections

These side effects are closely monitored and managed during and after treatment.[1][2][3]

Patient Eligibility

Eligibility criteria for varnimcabtagene autoleucel treatment typically include:

  • Diagnosis of relapsed or refractory CD19+ acute lymphoblastic leukemia or non-Hodgkin lymphoma
  • Previous treatment with at least two lines of systemic therapy
  • Adequate organ function and performance status
  • No active, uncontrolled infections
  • No history of certain autoimmune diseases or central nervous system disorders

Specific eligibility criteria may vary depending on the particular clinical trial or treatment protocol.[1][2][3]

Future Prospects

Varnimcabtagene autoleucel represents a promising advancement in the field of cancer immunotherapy. As clinical trials progress, researchers hope to gain more insights into its long-term efficacy, optimal dosing strategies, and potential applications in other types of cancers. The development of this therapy also contributes to the broader understanding of CAR T-cell therapies and their role in treating various forms of cancer.

Aspect Details
Drug Name Varnimcabtagene Autoleucel (ARI-0001)
Type of Therapy CAR T-cell therapy
Target Diseases Relapsed/refractory Non-Hodgkin Lymphoma, CD19+ Acute Lymphoblastic Leukemia
Administration Intravenous infusion
Main Objectives of Trials Assess efficacy, safety, and tolerability; evaluate response rates and duration; measure overall survival and progression-free survival
Key Inclusion Criteria CD19+ blood cancers, relapsed or refractory to previous treatments, specific age ranges (varies by trial)
Key Exclusion Criteria Active infections, severe organ dysfunction, previous CAR T-cell therapy, certain concurrent medical conditions
Primary Endpoints Response rates, progression-free survival
Secondary Endpoints Overall survival, duration of response, safety assessments, CAR T-cell persistence
Special Considerations Monitoring for cytokine release syndrome (CRS) and neurotoxicity (ICANS)

FAQ

  • What is Varnimcabtagene Autoleucel? Varnimcabtagene Autoleucel, also called ARI-0001, is a type of CAR T-cell therapy. It's made by taking a patient's own T-cells (a type of immune cell) and changing them in a lab to recognize and attack cancer cells that have a specific protein called CD19 on their surface.
  • What types of cancer is Varnimcabtagene Autoleucel being tested for? It's being tested in clinical trials for blood cancers that have the CD19 protein, including relapsed or refractory non-Hodgkin lymphoma and acute lymphoblastic leukemia. These are cancers that have come back after treatment or haven't responded well to other treatments.
  • How is Varnimcabtagene Autoleucel given to patients? The therapy is given as an infusion into a vein. Before the infusion, patients usually receive chemotherapy to prepare their body for the CAR T-cells. The modified T-cells are then infused back into the patient's body to find and fight the cancer cells.
  • What are the main goals of the clinical trials studying Varnimcabtagene Autoleucel? The main goals are to check how well the therapy works (its efficacy) and how safe it is. Researchers are looking at things like how many patients respond to the treatment, how long the responses last, and what side effects might occur.
  • Who can participate in these clinical trials? The trials have specific criteria for who can join. Generally, they're for patients with certain types of blood cancers that haven't responded well to other treatments. There are age limits and other health requirements. Each trial has its own set of rules for who can participate.

Ongoing Clinical Trials on Varnimcabtagene Autoleucel

  • Infusion Study of ARI-0001 Cells for Patients with Resistant or Refractory CD19+ Acute Lymphoid Leukemia

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study Comparing ARI-0001 and Axicabtagene Ciloleucel for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

    Recruiting

    2 1 1 1
    Investigated drugs:
    The Netherlands

  • Study of ARI-0001 Cells for Children and Adolescents with Resistant or Refractory Acute Lymphoblastic Leukemia

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • CAR T-cell therapy: A type of treatment that uses a patient's own T-cells (a part of the immune system) that have been changed in a laboratory to help them find and destroy cancer cells.
  • CD19: A protein found on the surface of some types of blood cancer cells. CAR T-cells like Varnimcabtagene Autoleucel are designed to target cells with this protein.
  • Relapsed cancer: Cancer that has returned after a period of improvement.
  • Refractory cancer: Cancer that does not respond to treatment.
  • Non-Hodgkin lymphoma: A type of cancer that starts in white blood cells called lymphocytes, which are part of the body's immune system.
  • Acute lymphoblastic leukemia: A type of blood cancer that affects white blood cells called lymphocytes. It progresses quickly and needs immediate treatment.
  • Lentivirus: A type of virus used in the laboratory to introduce new genetic material into cells, like the instructions for making the CAR in CAR T-cell therapy.
  • Infusion: A method of delivering fluids, including medications, directly into a vein.
  • Cytokine Release Syndrome (CRS): A condition that can occur after some cancer treatments, including CAR T-cell therapy, where the immune system releases a large amount of inflammatory substances called cytokines.
  • ICANS: Immune effector Cell-Associated Neurotoxicity Syndrome, a potential side effect of CAR T-cell therapy that affects the nervous system.
  • Measurable Residual Disease (MRD): A very small number of cancer cells that remain in the body during or after treatment, which can only be detected using very sensitive tests.
  • Progression-free survival: The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • Overall survival: The length of time from the start of treatment for a disease that patients are still alive.

References

  1. http://clinicaltrials.eu/trial/study-comparing-ari-0001-and-axicabtagene-ciloleucel-for-patients-with-relapsed-or-refractory-non-hodgkin-lymphoma/
  2. http://clinicaltrials.eu/trial/infusion-study-of-ari-0001-cells-for-patients-with-resistant-or-refractory-cd19-acute-lymphoid-leukemia/
  3. http://clinicaltrials.eu/trial/study-of-ari-0001-cells-for-children-and-adolescents-with-resistant-or-refractory-acute-lymphoblastic-leukemia/